Dr. Reddy's Laboratories is India's second-largest pharmaceutical exporter — $3.5 billion in consolidated revenue (FY25), with the US market contributing approximately 44%. The US business is built on a continuously replenishing pipeline of Abbreviated New Drug Applications (ANDAs) — applications to the FDA to manufacture and market a generic version of a branded drug.
How to Read an ANDA Pipeline
Not all ANDAs are equal. The value of an ANDA depends on: (1) the innovator drug's sales before patent expiry — higher sales means a larger market to capture; (2) the number of generic competitors — fewer competitors means higher market share; (3) whether Dr. Reddy's is the first-to-file (FTF) — the first generic filer gets 180 days of exclusivity, during which it and the innovator are the only two players. FTF exclusivity can generate ₹500-2,000 crore in revenue in just 6 months.
The gRevlimid Opportunity
Dr. Reddy's was among the first-to-file generics for Revlimid (lenalidomide) — a blockbuster cancer drug with $7 billion in global sales. The gRevlimid launch in the US (structured settlement with Celgene/BMS) provided a multi-year revenue stream that significantly boosted Dr. Reddy's US revenue. Understanding how to identify and model such pipeline catalysts is the highest-value analytical skill in pharma investing.
- Consolidated revenue FY25: ~$3.5 billion
- US revenue share: ~44%
- ANDAs filed: 300+ cumulative | Pending approvals: 100+
- FTF opportunities in pipeline: 15-20 (management estimate)
- EBITDA margin: ~24-26%
🔍 BBS Insight
The ANDA pipeline is Dr. Reddy's most valuable asset — and it is disclosed (partially) in every annual report. Go to the investor relations section, find the ANDA filing summary, and identify: (1) total pending approvals; (2) number with first-to-file status; (3) any Para IV certifications (patent challenges — highest risk, highest reward). This analysis gives you a 2-3 year revenue outlook that no sell-side report captures better than reading the primary source directly.